Table 2.
Characteristic of studies included in the meta-analysis of the association of APOE ε4 gene polymorphism with the risk of ischemic stroke
| No. | First author, year | Origin | Ethnicity | Sample size, n (case/control) | PCR method | Matching criteria | M/F (case/control) | Age (case/control) | HWE | Source of control | Quality score |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Saidi [17], 2007 | Tunisia | Caucasian | 228/323 | PCR-RFLP | Age-sex | 114/114 117/146 | 61.5±12.1/60.9±12.8 | Yes | PB | 12 |
| 2 | Gao [18], 2006 | Chinese | Asian | 100/100 | PCR-DHPLC | Age-sex | 71/29 71/29 | 60.08±10.77/60.9±10.64 | No | HB | 11 |
| 3 | Giassakis [19], 2007 | Greece | Caucasian | 100/96 | Nested PCR-RFLP | Age-sex | 70/30 66/30 | 60.7±9.8/61.3±9.8 | No | PB | 9 |
| 4 | Nakata [20], 1997 | Japan | Asian | 55/61 | PCR-RFLP | Age-sex | 25/30 30/31 | 66±14/67±8 | Yes | PB | 12 |
| 5 | Abboud [21], 2008 | Beligum | Caucasian | 237/326 | PCR | NA | NA | NA | Yes | PB | 12 |
| 6 | Kang [22], 2006 | Korea | Asian | 194/168 | PCR-sequencing | Age | 116/78 94/74 | 62±9.5/62.3±6.3 | No | HB | 11 |
| 7 | Tamam [23], 2009 | Turkey | Asian | 65/30 | PCR | Age-sex | 44/21 10/20 | 65.5±14.3/61.9±14.7 | No | NA | 6.5 |
| 8 | Catto [24], 2000 | UK | Caucasian | 513/289 | PCR-RFLP | Age-sex | 297/295 150/139 | 73 (64-80)/72.5 (58-79) | Yes | HB | 12 |
| 9 | Karttunen [25], 2002 | Finland | Caucasian | 46/104 | PCR-RFLP | Age-sex | 27/19 59/45 | 46 (15-60)/46 (17-62) | No | PB | 10 |
| 10 | Jin [26], 2004 | China | Asian | 226/201 | PCR-RFLP | Age-sex | 129/97 109/92 | 48.5±3.4/47.1±2.4 | Yes | PB | 11 |
| 11 | Pezzini [27], 2005 | Italy | Caucasian | 163/158 | Multiplex-PCR | Age-sex | 84/79 85/73 | 35±7.5/34±6.1 | No | HB | 11 |
| 12 | Luthra [28], 2002 | India | Asian | 63/57 | PCR-RFLP | NA | NA | 56.4±13.1/39.4±8 | No | HB | 8 |
| 13 | Wang [29], 2009 | China | Asian | 396/396 | PCR-RFLP | Age-sex | 209/187 201/195 | 57.3±8/57.2±8.09 | Yes | HB | 12 |
| 14 | Couderc [30], 1993 | France | Caucasian | 69/68 | PCR-RFLP | Age-sex | 36/33 33/35 | 72.3±11.6/72.1±11.5 | No | NA | 7.5 |
| 15 | MacLeod [31], 2001 | UK | Caucasian | 266/225 | PCR-RFLP | NA | 150/116 94/105 | 65.7±12.2/77±1 | Yes | PB | 9 |
| 16 | Kokubo [32], 2000 | Japan | Asian | 201/1,126 | PCR-RFLP | NA | 187/135 334/792 | 67.9±11/64.3 vs. 10.5 | No | PB | 8 |
| 17 | Souza [33], 2003 | Brazil | Caucasian | 107/100 | PCR-RFLP | Age-sex | NA | 68.8±9.17/69.4±8.29 | No | NA | 6 |
| 18 | Morrison [34], 2002 | US | Caucasian | 218/964 | PCR-RFLP | Age-sex | 113/105 415/549 | 56.6±0.4/53.9±0.1 | Yes | PB | 13 |
| 19 | Pezzini [35], 2004 | Italy | Caucasian | 124/147 | PCR-RFLP | Age-sex | 68/56 80/67 | 34.7±7.3/34.8±6.1 | No | HB | 9 |
| 20 | Kessler [36], 1997 | Germany | Caucasian | 227/225 | PCR-RFLP | Age-sex | 108/119 108/117 | 62.3±14.2/62.6±14 | No | HB | 9 |
| 21 | Mcllroy [37], 2002 | Ireland | Caucasian | 64/71 | PCR-RFLP | Smoking-hypertension | 37/27 14/57 | 73.8±8.1/74.3±7.6 | No | HB | 9 |
| 22 | Chowdhury [38], 2001 | Bangladesh | Asian | 147/190 | PCR-RFLP | NA | 117/30 129/61 | 57.9±11.1/60.3±9.6 | No | HB | 7 |
| 23 | Atadzhanov [39], 2013 | Zambia | Caucasian | 23/116 | TaqMan assay - direct sequencing | Age-sex | NA | NA | Yes | HB | 13 |
| 24 | Baum [40], 2006 | Hong Kong | Asian | 246/336 | PCR-RFLP | Age | 134/112 152/184 | 70.7±12/71.0±5.9 | Yes | HB | 12 |
| 25 | Frikke-Schmidt [41], 2001 | Denmark | Caucasian | 738/8,938 | PCR-RFLP | Age-sex | 457/281 4,022/4,916 | 63.2±0.4/57.2±0.2 | Yes | PB | 11 |
| 26 | Um [42], 2003 | Korea | Asian | 196/379 | PCR-RFLP | NA | NA | NA | Yes | HB | 8 |
PB = Population based; HB = hospital based; PCR-RFLP = polymerase chain reaction-restriction fragment length polymorphism; NA = not applicable.